Cybin (CYBN) announced that it has engaged Thermo Fisher (TMO) to support the Phase 3 clinical supply and potential commercial manufacturing of CYB003, the company’s proprietary deuterated psilocin program in Phase 3 development for the adjunctive treatment of Major Depressive Disorder.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYBN:
- Cybin CEO to Speak at Healthcare Showcase, Highlighting Innovations in Mental Health Treatment
- Psychedelic: Compass, GH Research, MindMed report quarterly earnings
- Cybin announces USPTO patent in support of CYB003 program
- Cybin Secures New U.S. Patent for CYB003 Program in Major Depressive Disorder
- Cybin CEO to Speak at Milken Institute Global Conference on Medical Breakthroughs